GSK1349572 + Raltegravir + GSK1349572 Placebo + Raltegravir Placebo
Phase 3Completed 0 watching 0 views this week📈 Rising
77
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 24
Phase 35
ApprovedIndication / Disease
Infection, Human Immunodeficiency Virus
Conditions
Infection, Human Immunodeficiency Virus, HIV Infections
Trial Timeline
Oct 26, 2010 → Feb 2, 2021
NCT ID
NCT01231516About GSK1349572 + Raltegravir + GSK1349572 Placebo + Raltegravir Placebo
GSK1349572 + Raltegravir + GSK1349572 Placebo + Raltegravir Placebo is a phase 3 stage product being developed by Shionogi for Infection, Human Immunodeficiency Virus. The current trial status is completed. This product is registered under clinical trial identifier NCT01231516. Target conditions include Infection, Human Immunodeficiency Virus, HIV Infections.
Hype Score Breakdown
Clinical
27
Activity
18
Company
10
Novelty
9
Community
10
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT01231516 | Phase 3 | Completed |
Competing Products
20 competing products in Infection, Human Immunodeficiency Virus